Chloe Orkin, MBBCH, MSc, FRCP; Sharon L. Walmsley, MSc, MD, FRCPC
Jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
This activity is intended for HIV specialists engaged in the care of patients with HIV.
Women with HIV require care outside of traditional HIV management, particularly concerning pregnancy and contraceptives. Clinicians require updates on new data and guidelines about appropriate antiretroviral therapy (ART) regimens during pregnancy as well as strategies for multidisciplinary care. Dr. Chloe Orkin and Dr. Sharon Walmsley discuss a patient who is virally suppressed and would like to conceive. They discuss ART regimens, viral monitoring, collaboration with an obstetrician/gynecologist, intra- and postpartum care, breastfeeding, and contraceptives.
After completing this activity, the participant should be better able to:
- Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder
Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom
Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Toronto Hospital, University Health Network
University of Toronto Department of Medicine
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare
Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., ViiV Healthcare
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Instructions to Receive Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by PIM and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
CME Questions – PIM Contact Information
Integritas Contact Information
For all other questions regarding this monograph, please contact Integritas via email at email@example.com.
Computer System Requirements
Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), Chrome or Firefox MAC
MAC OS 10.2.8:
Internet Explorer is not supported on the Macintosh.